

Pfizer Limited

The Capital, 1802/1901,

Plot No. C - 70, G Block, Bandra Kurla Complex,

Bandra (East), Mumbai 400 051.

Tel: +91 22 6693 2000 Fax: +91 22 2654 0274

May 13, 2025

The Corporate Relationship Dept.

The Listing Dept.

BSE Limited The National Stock Exchange of India Ltd.

1st Floor, P.J.Towers Exchange Plaza, 5th Floor, Plot No. C/1,

Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E)

Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Board Meeting to consider and approve the Audited Financial Results for the quarter and Financial Year ended March 31, 2025.

Ref.: Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015.

This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, May 19, 2025 *inter alia*, to consider, approve and take on record the Audited Financial Results of the Company for the quarter and Financial Year ended March 31, 2025 and to consider recommendation of dividend, if any, for the Financial Year ended March 31, 2025.

Further, pursuant to the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading), Regulations, 2015 and in accordance with "Pfizer Limited – Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders", the Trading Window for dealing in shares of the Company has been closed from Monday, March 31, 2025 (close of business) till 48 hours after the said Audited Financial Results are made public on May 19, 2025.

Request you to please take the above on record.

Thanking you,

Yours truly,

For **Pfizer Limited**

Prajeet Nair

Director – Corporate Services & Company Secretary

Cc: National Securities Depository Limited (NSDL)
Central Depository Services (India) Limited (CDSL)
KFin Technologies Limited

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com

Website: www.pfizerltd.co.in